Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-01-17 00:00:00 ET · period of report 2024-01-12 · accession 0001787306-24-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-17 | 2024-01-12 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | A - Grant | $0.00 | +125.0K | 627.0K | +25% | $0 |
| D | 2024-01-17 | 2024-01-12 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | A - Grant | $0.00 | +410.0K | 410.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-12 | A | A | 125,000 | $0.00 | 627,019 | D | — | — | (F1) Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. |
| 2 | Derivative | Stock Option (right to buy) | 2024-01-12 | A | A | 410,000 | $0.00 | 410,000 | D | $3.64 · — to 2034-01-12 | 410,000 Common Stock | (F2) 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. |